Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.
Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
AMIA Annu Symp Proc. 2023 Apr 29;2022:1227-1236. eCollection 2022.
Remdesivir has been widely used for the treatment of Coronavirus (COVID) in hospitalized patients, but its nephrotoxicity is still under investigation. Given the paucity of knowledge regarding the mechanism and optimal treatment of the development of acute kidney injury (AKI) in the setting of COVID, we analyzed the role of remdesivir and built multifactorial causal models of COVID-AKI by applying causal discovery machine learning techniques. Risk factors of COVID-AKI and renal function measures were represented in a temporal sequence using longitudinal data from EHR. Our models successfully recreated known causal pathways to changes in renal function and interactions with each other and examined the consistency of high-level causal relationships over a 4-day course of remdesivir. Results indicated a need for assessment of renal function on day 2 and 3 use of remdesivir, while uncovering that remdesivir may pose less risk to AKI than existing conditions of chronic kidney disease.
瑞德西韦已广泛用于住院患者的冠状病毒(COVID)治疗,但它的肾毒性仍在研究中。鉴于 COVID 背景下急性肾损伤(AKI)发生机制和最佳治疗方法的知识匮乏,我们通过应用因果发现机器学习技术,分析了瑞德西韦的作用,并构建了 COVID-AKI 的多因素因果模型。使用 EHR 的纵向数据,将 COVID-AKI 的危险因素和肾功能指标表示为时间序列。我们的模型成功地再现了肾功能变化的已知因果途径以及彼此之间的相互作用,并在瑞德西韦的 4 天疗程中检查了高级因果关系的一致性。结果表明,需要在第 2 天和第 3 天评估肾功能并使用瑞德西韦,同时揭示瑞德西韦对 AKI 的风险可能低于慢性肾病等现有情况。